• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Moringa Acquisition Corp

    2/13/23 12:41:49 PM ET
    $MACA
    Blank Checks
    Finance
    Get the next $MACA alert in real time by email
    SC 13G 1 sc_13g_moringaacquisition.htm
     
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     
     

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. *)
     
     

    Moringa Acquisition Corp
    (Name of Issuer)
    Class A ordinary shares, par value $0.0001 per share
    (Title of Class of Securities)
    G6S23K108
    (CUSIP Number)
    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)
     
     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [X]  Rule 13d-1(b)
    [   ]  Rule 13d-1(c)
    [   ]  Rule 13d-1(d) 
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     




    CUSIP No. G6S23K108
     
     
      1.  
      NAME OF REPORTING PERSONS
     
      Aristeia Capital, L.L.C.
     
     
      2.  
      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)  ☐        (b)  ☐
     
     
     
      3.  
      SEC USE ONLY

     
     
     
      4.  
      CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware
     
    NUMBER OF
    SHARES
      BENEFICIALLY  
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
      5.  
      SOLE VOTING POWER
     
    1,001,848 (1)
    6.  
      SHARED VOTING POWER
     
      0
    7.  
      SOLE DISPOSITIVE POWER
     
      1,001,848 (1)
    8.  
      SHARED DISPOSITIVE POWER
     
      0
     
      9.  
      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      1,001,848 (1)
     
     
    10.  
      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
      ☐
     
     
    11.  
      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      8.36 %
     
     
    12.  
      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
      IA, OO
     

    (1)
     
    Aristeia Capital, L.L.C. is the investment manager of, and has voting and investment control with respect to the securities described herein held by, one or more private investment funds.
     
     
       



    Item 1.
    (a).
    Name of Issuer:
       
    Moringa Acquisition Corp (the “Issuer”)
    Item 1.
    (b).
    Address of Issuer’s Principal Executive Offices:
       
    250 Park Avenue, 7th Floor
    New York, New York 10017
     
    Item 2.
    (a).
    Name of Person Filing:
    Item 2.
    (b).
    Address of Principal Business Office or, If None, Residence.
    Item 2.
    (c)
    Citizenship.
       
    Aristeia Capital, L.L.C.
    One Greenwich Plaza, 3rd Floor
    Greenwich, CT 06830
    Delaware limited liability company
     
    Item 2.
    (d).
    Title of Class of Securities:
       
    Class A ordinary shares, par value $0.0001 per share (“Shares”)
    Item 2.
    (e).
    CUSIP Number:
       
    G6S23K108

    Item 3.
    If this statement is filed  pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:
     
    (a)
    ☐
    Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
     
    (b)
    ☐
    Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
     
    (c)
    ☐
    Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
     
    (d)
    ☐
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    ☒
    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
     
    (g)
    ☐
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
     
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j)
    ☐
    Group, in accordance with  § 240.13d-1(b)(1)(ii)(J).

    Item 4
    Ownership
     
    The following is information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 as of 12/31/2022.
     
    Items 5-9 and 11 of the cover page to this Schedule 13G are incorporated herein by reference.
     
     
    (a)
    Amount beneficially owned:  1,001,848
     
    (b)
    Percent of Class:  8.36 %
     
    (c)
    Number of shares as to which such person has:
       
    (i)
    sole power to vote or direct the vote:  1,001,848
       
    (ii)
    shared power to vote or direct the vote:  0
     
     
    The percentage of Shares reported to be beneficially owned by the Reporting Persons is based on 11,980,000 Shares outstanding as of November 10, 2022, as reported in the Issuer’s Form 10-Q for the quarterly period ending September 30, 2022 filed with the SEC on November 14, 2022.
     
    Item 5.
    Ownership of Five Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [] .

    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
    N/A
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
     
    N/A
    Item 8.
    Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
     
    N/A
    Item 9.
    Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
     
     
    N/A
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    February 13, 2023
         
       
    ARISTEIA CAPITAL, L.L.C.
           
       
    By:
    /s/ Andrew B. David
         
    Name: Andrew B. David
         
    Title:   Chief Operating Officer



    Exhibit 99.1
    JOINT FILING AGREEMENT
    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the Class A ordinary shares, par value $0.0001 per share, of Moringa Acquisition Corp. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.

    February 13, 2023
         
       
    ARISTEIA CAPITAL, L.L.C.
           
       
    By:
    /s/ Andrew B. David
         
    Name: Andrew B. David
         
    Title:   Chief Operating Officer


    Get the next $MACA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MACA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MACA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

      Report covers Silexion Therapeutics (NASDAQ:SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company's impressive clinical achievements and unique approach alongside industry drivers including the increasing M&A activity in the space Silexion Therapeutics (NASDAQ:SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ:MACA), Silexion presents an interesting opportunity in the rap

      9/9/24 7:32:00 AM ET
      $MACA
      $SLXN
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

      MODI'IN, Israel and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Ltd. ("Silexion"), a clinical-stage, oncology-focused biotechnology company and Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination") with Biomotion Sciences (the "combined company"), a recently formed entity. The combined company's name is changing from Biomotion Sciences to "Silexion Therapeutics Corp", and its ordinary shares and warrants are expected to begin trading on Nasdaq under the tickers "SLXN" and "SLXNW", respectively, on August 16

      8/15/24 4:05:00 PM ET
      $MACA
      Blank Checks
      Finance
    • Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp

                                             Silexion's first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer which harbors an oncogene believed to be a major driver of the cancer In combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months) Modi'in, Israel and New York, New York, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. ("Silexion"), a cli

      2/22/24 8:27:00 AM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Moringa Acquisition Corp

      SCHEDULE 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      8/27/24 11:00:41 AM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form 15-12G filed by Moringa Acquisition Corp

      15-12G - Moringa Acquisition Corp (0001835416) (Filer)

      8/26/24 9:49:09 AM ET
      $MACA
      Blank Checks
      Finance
    • Moringa Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - Moringa Acquisition Corp (0001835416) (Filer)

      8/21/24 4:05:08 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/14/24 6:28:12 AM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/12/24 4:24:57 PM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/8/24 1:16:56 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Hudson Bay Capital Management Lp disposed of $4,253,473 worth of Class A Ordinary Shares (401,271 units at $10.60)

      4 - Moringa Acquisition Corp (0001835416) (Issuer)

      8/24/23 2:31:41 PM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form 3: New insider Hudson Bay Capital Management Lp claimed ownership of 401,271 units of Class A Ordinary Shares

      3 - Moringa Acquisition Corp (0001835416) (Issuer)

      4/5/23 4:59:51 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

      JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

      3/21/22 4:05:00 PM ET
      $DRTS
      $MACA
      $VBLT
      Medical/Dental Instruments
      Health Care
      Blank Checks
      Finance